Clinical Trial

Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2021 (before its estimated January 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Prospective, multicenter, single-arm, open label, interventional basket trial to evaluate autologous tumor-infiltrating lymphocytes (TILs) infusion followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparation for the treatment of patients with advanced or metastatic refractory gynecological cancer including cervical, ovarian, endometrial and breast carcinoma.
Trial Details
NCT Number NCT05152797
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Collaborators: Tongji Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University
Conditions Tumor Infiltrating Lymphocytes
Enrollment 91 participants
Start Date 2022-01-01
Primary Completion 2024-01-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2021-12-10